Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's secret Facebook page!
Give me your Email so I get you in!
FN
I like that !!
An other great promoter:
The Behavioral Economist
http://seekingalpha.com/article/1802992-nanoviricides-incorporated-a-biotech-innovator-bound-only-by-its-own-ambition
NanoViricides Incorporated: A Biotech Innovator Bound Only By Its Own Ambition
Nov 4 2013, 15:32 | about: NNVC
BOOKMARK / READ LATER
X
Bookmark
Save this article to continue reading from your iPad Get the app »
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
As 2013 approaches its inevitable end, the investment world has begun to debate the presence of a "biotechnology bubble". That is to say, a discussion has begun with the objective of concluding whether or not the biotechnology industry has become an over-priced market fueled by its own momentum. If it has, the potential end result is an industry wide crash which will adversely affect companies and shareholders alike. However, this is unlikely. Sure, similar yearlong run-ups in other industries have been met with inevitable demise (most notably the housing crash and the dotcom boom) but biotechnology is different. Biotechnology is an industry in a class all its own. It is fueled by innovation and genius. Genius innovations, in the medical world, will always have a buyer. That type of market evolution, coupled with inventive brilliance, creates an atmosphere of boundless potential growth.
Consider for a moment what it is that fuels innovation. What is it that motivates someone to innovate? Why do some of us choose to take on the task of solving problems currently without solutions? Why do some of us even feel capable of such? These are difficult questions to answer, because the fact is that innovation, on some level, requires audacity. At some point during the innovative process one looks at a challenge and says to oneself "I can succeed where all others have failed." Innovation requires confidence, knowledge, resources, and a complete immunity to the fear of failure that so often plagues the common man. These types of people, these "innovators", are the backbone of the biotechnology world. As the calendar prepares to turn into 2014, there is one company that is showing signs of being the most ambitious innovator of them all. That company is NanoViricides Incorporated (NNVC), and their ambitions are, by traditional standards, almost immeasurable.
Who is NanoViricides?
Who is NanoViricides?
NanoViricides is a developmental stage, nano-biopharmaceutical company, intent on unlocking the solution to viral infections. They believe that they possess a technology capable of treating, and perhaps even curing, some of the most prolific of human ailments. Take a moment to look at their current pipeline of drugs in development, and consider what the long term benefits could be for the successful advancement, approval, and distribution of any one of them.
(click to enlarge)
Most biotechnology companies develop drugs for a specific market niche disease. Their targets are smaller. Their ambitions are more tempered. Their long term consequences make less of an impact. That is not to say that other company's developments aren't noteworthy or significant; they certainly are. However, there is a clear distinction between a capable market niche product, and a potentially revolutionary catalyst for widespread market evolution. NanoViricides is obviously in pursuit of the latter. They are developing potential treatments for the flu, HIV, hepatitis C, the Ebola virus, and Epidemic Kerato-Conjunctivitis. The collective addressable markets for those conditions are well into the billions. To define such developmental projects as ambitious would be quite an understatement.
What is perhaps most impressive though isn't the company's ambition, but rather their technology. After all, it is one thing to want to do something, it is entirely another to potentially have the ability to do it.
The Development of NanoViricides
There is NanoViricides Incorporated (the company) and there are nanoviricides (the technology). For the sake of minimizing any confusion in this segment, the objective here is to address the technology specifically.
Before one is capable of even a cursory understanding of nanoviricides however, one must understand the basics of what makes a virus. In the simplest of terms, a virus is essentially an intelligent infection. It has a survival instinct. A virus replicates inside living cells. It avoids isolation and targeted treatment, and can range widely in shape and design. Furthermore, the average virus is about one one-hundredth the size of the average bacterium. In fact, viruses are so elusive, strong, prevalent and self-sustaining, that a sub-specialty of microbiology called virology is committed solely to the research and understanding of viruses. What virology tells us is that while viruses provoke an immune response in humans capable of reducing their effects to a level of dormancy, the virus always remains. That is one of the many reasons why the ongoing battle between the medical world and viruses seems like one of endurance as opposed to one of resolution.
Enter into the fold the technology known as nanoviricides. The goal of nanoviricides is simple; find, encapsulate, and destroy. In other words, detect the virus, isolate it, and extinguish it. This is not a vaccine, an antibiotic, or a standard anti-viral drug. This is a technology designed to bind to a virus particle, wrap and isolate it, and then terminate it. You see, a virus usually survives and prospers by attaching itself to receptors on a cell surface. This is part of the virus's intelligent evolution. However, nanoviricides essentially fool the virus into attaching instead to the nanoviricide agent. Once this occurs, a flexible glob then surrounds the virus and traps it. The virus then loses its active proteins that it needs to grow, and it is effectively neutralized.
(click to enlarge)
What nanoviricides represents is the next great step in the advancement of immunotherapeutic science. Viruses possess the ability to compromise one's capacity for efficient immune system function. Nanoviricides counter that in a way that has never before been developed.
Protecting the Technology
Inside the walls of NanoViricides Incorporated exists the leadership of the company's president and founder, Anil R. Diwan. Dr. Diwan is an innovator of the highest order. In his 25 years working in the biopharmaceutical industry, he has spent 20 of them as an entrepreneur. He has won several NIH SBIR (small business innovation research) awards and has led various other entities throughout his career.
In 1991 Dr. Diwan first developed the baseline technology for the evolution of his nanoviricides. He eventually came to call this technology "TheraCour", and had his invention successfully patented. As a result, NanoViricides Incorporated holds an exclusive, worldwide license to this technology for its antiviral drugs. The technology is protected by two very broad international patent applications. These patents cover compositions of matter, processes of manufacture, methods of use, and fields of use. It is, simply put, all encompassing.
With this technology and its patents in place, the company is advancing rapidly towards FDA submissions. They have already filed a pre-IND application with the FDA for their novel, first in class, influenza drug, FluCide.
What Makes NanoViricides Different?
More often than not, the first question that prospective investors ask when evaluating a developmental stage biotechnology company is this; "what makes this company stand out from the rest"?
That is a fair question. The truth of the matter is, every biotech company with a developmental pipeline all share one product; hope. So, in that respect, they are all the same. However, what tends to make one company different from the others is their technology, leadership, financial position, experience, and market potential. In the case of NanoViricides, the market potential is obvious. It is widespread and potentially massive. In terms of technology, and the way it is being applied, it is prospectively revolutionary. So that leaves one to consider the leadership, experience, and finances.
The team at NanoViricides is an accomplished one. The eight members of the company's executive team, combined with the members of the scientific advisory board, have contributed to the research, development, and processing of more than 25 drugs. Ten of these drugs are already approved, and the rest of them are in advanced clinical stages. While NanoViricides doesn't stand to profit from these achievements, it stands to reason that this track record of success with continue at NanoViricides.
Furthermore, the executive staff is not only accomplished, but also as innovative as its founder. The staff has long been at the forefronts of medical science and pharmaceutical technology. They have collectively contributed to the advancement of knowledge in such fields as polymeric micelles, multi-specific drug targeting, DNA, and gene therapy. Once again, this is a good sign. Innovative products, such as the development of nanoviricides with patented TheraCour technology, require innovative leaders.
In terms of the company's finances, they are quite healthy. In February the company raised 6 million dollars from equity investors. This was followed by an additional ten million dollars in September. As it stands currently, the company has controlled their research and development costs in an exemplary fashion, and has substantial cash in hand. The fiscal health of the company is strong.
Risks
It seems that in every article about a developmental stage biotech that the risk segment is the same. It touches upon the high costs associated with bringing drugs to trials. It summarizes the competition in the marketplace. It never fails to mention the dangers of an FDA denial. It is always the same. It is the same for good reason though. All of these are relevant concerns, and they should always be considered. In the case of NanoViricides, all these threats are relevant. However there is another risk that is worthy of being mentioned.
Ambition can be addictive. It can, in its own right, be a drug. For the ambitious man, or the ambitious company, every successful step only fuels a growing feeling of invincibility or inevitability. This is the biotech conundrum. While it requires audacity to fuel innovation, audacity can also lead to complacency. While it is the hope that such a shift in behavior doesn't occur at NanoViricides, the possibly of such is always present.
When a company has designed a technology capable of succeeding where all others have failed, the dangers of becoming too enamored with your own potential are all too real. NanoViricides must not allow this to happen. Pride and arrogance have long been proven to lead to downfall.
Conclusion
The biotechnology bubble is largely a myth. For the companies with true innovative science there is always going to be growth, profit, and potential. Health is not a riddle that can be solved. Life expectancy is never going to be "forever". That is the one common plight of the human condition; all of us are born with an expiration date. For that reason, there will always be a market for innovative medical breakthroughs.
NanoViricides is one of those companies. They haven't just designed a drug. They have developed a technology. That technology could become the new standard in the fight against life threatening viruses. Granted, all of their pipeline products are in pre-clinical phases, and there is an almost endless list of things that could go wrong on the road to noteworthy trials. However as it stands currently, these are afterthoughts. At this phase in development investors should concern themselves with potential, fiscal stability, and technology. In those three areas, NanoViricides is well ahead of the curve.
Opportunities to invest in a company capable of introducing paradigm shifting technology into the medical establishment are few and far between. Therefore, at these levels, this early in the process, investment in NanoViricides presents itself as a rare opportunity. Significant return on investment may be years away, but that return could well be substantial. Further consideration of NanoViricides as an investment vehicle is recommended for any investor with sizeable long term ambitions and equitable patience.
Hi changes_iv
We need a great videos reporter for NANO CLUB !
Are you in?
FN
I still likes $2000!
Ooopps!!
Sorry looks like you have to!
Just open a fake one if you want!
Just don't use it!
FN
Thanks D patent!
http://www.in-pharmatechnologist.com/Drug-Delivery/Elimiating-Viruses-the-NanoViricides-Way
Sorry, I couldn't paste it!
FN
Great Fantastic
We have weedie!!!
GOOOOOOOOOOOOOOOOOOOOOOO WEEEDDIIEEE !!!!!!!!!!!!!!
Daboze, Crossbone09
Just did it!!
See you on the other side!
FN
No you don't have too!
Just give me your email so you can get in!
FN
Yes it does!
But NNVC still new on the AMEX.
Give it some times! We are doing great anyway.
FN
Puffer!
If you need some space in my bagpack when we will hike with weedie, you need to be part of the
NANO CLUB in order to organiize it !!
FN
Great !!!
Just didi it!
Just didi it!
It looks like the PR effect is working today!
Hey Echo20
Come and join us on NANO CLUB!
We have a nice group !
FN
I am glad that they work on their Website !
It's very polished !
FN
We will see!
Weedy
This is a new club that I created after
Nanopatent idea!
When you are ready just send me your Email!
Ciao
FN
Aspenmp
Just send me your email on the private messages!
Thanks
FN
Yes! I think it's going to be fun!
I am reading "Digital FORTRESS".
I red the Da Vinci code and loved it.
Weedie,
I know Nano Patent asked you before!
NANO CLUB is safe and secret.
It would be great to have you on board!
We need a feminine help for ideas about creating events like Hawaii!
rearden and I are talking about planing it !
Again, don't feel obliged but we will love to have you on board!
FN
Does anyone know what the expected time frame is for the tests on H7N9 and MERS (among others) that PHE made an agreement to do in July?
It's mean "Hell"
I like his books!
That's a dream who's becoming reality!!
The power of the internet - the global village, our virtual Hawaii, here and now!!
Give it a week!
After this news, investors will start to invest in the next 2 days!
NNVC is introducing its potential !
FN
Agreed! We are going to meet very soon!
Got it !
Did it!
This is BIG !
A lot of people listen to him.
I was wondering when NNVC was a penny stock If Cramer new about the company and what would he said about it!
BOOYAH !!!!!!!
FN
Yes I paste it
Did it again
Let me know
Just did!
another_voice
Are inetested to join us at "N A N O C L U B" ?
It would be great to have you on board?
FN
Bon travail !
Hope it still there!
No pressure! When you want and if you are decided, leave me your email.
FN